WO2010040529A1

WO2010040529A1 - Bag, bag set, method and treatment device for treating at least one blood component

Info

Publication number: WO2010040529A1
Application number: PCT/EP2009/007234
Authority: WO
Inventors: Edgar Bandow
Original assignee: Fresenius Kabi Deutschland Gmbh
Priority date: 2008-10-09
Filing date: 2009-10-08
Publication date: 2010-04-15
Also published as: DE102008051123A1; EP2349376A1

Abstract

The present invention relates to a bag (1) for receiving at least one blood component (5) for the treatment thereof in the interior (3) of the bag (1) by means of an adding unit (7) for adding at least one UV-activatable agent to the interior (3) of the bag (1). The present invention further relates to a bag set having at least one bag (1) according to the invention, and to a method and to a treatment device for treating a blood component (5) utilizing the bag (1).

Description

Besehreibung

A pouch, bag set, method and treatment device for treating at least one blood component

The present invention relates to a bag for treating at least one blood component according to the preamble of claim 1 and to a bag set according to claim 11. Furthermore, the present invention relates to a method according to claim 13 and a treatment device according to claim 22.

In the treatment of certain pathological conditions of a patient, blood or components thereof are exchanged and / or added thereto. Not least to avoid possible immune reactions or intolerance phenomena, a patient receives only those blood components from the blood of a donor, which he actually needs. Furthermore, by separating the blood into its components, the handling and storage of the respective relevant blood component can be simplified. For this purpose, the appropriate blood components are isolated from a previously collected whole blood sample, purified or otherwise treated and re-infused to the same or another person. The whole blood sample may come from the patient himself or from another donor.

One common method of treating blood components is photopheresis, a form of apheresis in which blood is contacted with photoactivatable pharmaceuticals which are subsequently activated with UV light. Photopheresis is used, for example, in the context of the therapy of cutaneous T-cell lymphomas. The leukocyte film is separated from the whole blood, mixed with 8-methoxypsoralen (8-MOP), exposed to UV light and subsequently re-injected or infused into the donor (patient). Due to light activation, the 8-methoxypsoralen irreversibly binds to both strands of DNA. The photochemically damaged T cells reinfused to the patient appear to elicit a beneficial cytotoxic effect on T cell development. Photopheresis is also used in patients with allograft rejection, autoimmune diseases or ulcerative colitis.

A corresponding apparatus for separating whole blood is known, for example, as "Therakos" (THERAKOS, Inc. USA, Exton, PA 19341, United States), which uses a total blood volume of about 750 ml taken in three successive withdrawal cycles for a whole blood flow of 10-40 ml / min and after

Centrifugation coagulated with heparin. The so-called "buffy coat" (leucocytes and platelets, about 240 ml) is transferred together with about 300 ml of plasma and 200 ml of saline into a collection bag and added as a UV-activatable drug 8-MOP.The total duration of this process is about 3, 5-4 hours per session requires a high extracorporeal volume during separation as well as the use of, for example, heparin as an anticoagulant and is generally associated with a high expenditure of time and money A pouch system and method for inactivating pathogens more relevant Separated blood components by means of photopheresis is disclosed, for example, in EP 1 902 740 A1. The object of the present invention is to specify a further bag, a suitable bag set, a method and a treatment device for treating at least one blood component.

The object of the invention is achieved by a bag having the features of claim 1. The pouch of the invention is suitable for receiving at least one blood component for treating or pathogen inactivating it in an interior of the pouch using UV light, and has an adding means for adding at least one UV activatable agent to the interior of the pouch.

A "blood component" as used herein refers to a component of the blood, such as plasma, erythrocytes, leukocytes or platelets, or combinations thereof, and may be obtained by centrifuging a whole blood sample.

The blood component may have been obtained by centrifuging a blood sample, in particular a whole blood sample, in a bag and being distinguished in that it has not left the bag until further treatment thereof, in particular by irradiation.

The blood component may be distinguished by the fact that it has not reached the latter by transferring it from a vessel into the bag in which it is irradiated.

The "plasma" forms the fluid, cell-free component of the blood. A plasma exchange is used, for example, in the treatment of neurological diseases, such as For example, Guillain-Barre syndrome, multiple sclerosis, myasthenia gravis, Lamber-Eaton syndrome.

The "leukocytes" are part of the immune system and in leukemia individual subgroups of leukocytes change

Tumor cells. The most commonly affected are the lymphocytes. Tumor cells of this type impair the formation of erythrocytes, healthy leukocytes and platelets. Affected patients suffer from tiredness, paleness, bleeding tendency. They are also more susceptible to infections because the degenerate leukocytes can no longer fulfill their actual task of immune response.

The "taking up of at least one blood component for its treatment inside the bag" means according to the invention that at least one, eg the above-mentioned, blood component is taken up in a portion of the bag and treated in the same for example, by introducing the at least one blood component into the bag in an online process or offline process. According to the invention, ingestion is generally understood as meaning a "presence" of the blood component, and the component is also present in the interior of the pouch when it contains whole blood.

The treatment or purification of the at least one blood component in the interior of the bag is carried out using UV light. The "use of UV light" herein includes the participation of UV light in the treatment of the at least one blood component, but is not limited to the exclusive use of UV light , such as irradiation with light other wavelength ranges, adding chemical substances, heat or cold, a sterilization process or the like, can be used.

The "pouch" of the present invention may be made of a material suitable for receiving and treating blood components, such as polyvinyl chloride, polyethylene, polypropylene Suitable materials are well known to one skilled in the art and include, for example, those described in EP 1 902 740 Al or the

WO 2005/004862 A2 specified materials. Reference is hereby made in full to the relevant disclosures of said documents.

For treating the at least one blood component in the interior of the bag according to the invention, the bag has at least one section of UV-transmissive or transmissive material suitable for the respective photo-treatment. This means that at least a portion of the bag is designed so that UV light of the desired wavelength can penetrate into the interior of the bag and be used there to treat the at least one blood component. The bag may be completely UV-transparent and / or UV-transparent as well. In addition, portions of the bag may be completely opaque and, for example, carry labels and / or writable markable portions for labeling the bag, in which case the UV light may enter the interior without being able to penetrate it.

The bag according to the invention comprises an "adding device" for adding at least one UV-activatable active substance or medicament to the interior of the bag For example, delivery means may comprise means for adding the UV-activatable agent from outside the bag into the interior or from another portion inside the bag, again into the interior of the bag in which the blood component is present. An addition from outside can be done for example via arranged for this purpose reservoirs, supply lines, valves and other components. The components which come into direct contact with the UV-activatable active ingredient can be made of or have a material which does not interact with the UV-activatable active ingredient, is easy to sterilize and is free of pathogens.

Advantageous developments of the present invention are the subject of the dependent claims.

The addition device may be designed such that it does not serve as a reservoir for at least temporary storage of the active substance. It may be further configured such that the active ingredient is not already present in the interior or another portion of the bag in the process of receiving the blood component into the interior of the bag. That is, the delivery device may be configured to allow the addition of the drug to the blood component upon ingestion of the blood component. In addition, the amount of active substance to be added to the interior of the bag can be variably adjusted and supplied at variable times.

Regardless of other features, the delivery device may open into a "lower" region of the bag inside the bag, ie, in a region of the bag remote from the center of rotation of the bag not suitable or provided for the discharge of blood components.

The adding device may be designed to take samples from inside the bag. This in turn can be done for example by means of membrane.

The addition device can be connected to fully or semi-automated control and / or regulating devices, with which an addition of the UV-activatable active ingredient can be continuous or in certain, for example fixed or depending on other conditions and circumstances, resulting time intervals.

The adding device may further be provided with suitable

Sensors can be coupled to measure certain parameters, and the addition of the active ingredient can be carried out according to the measured value of the respective parameter.

The adding device can be designed such that it is not a device for expressing plasma.

The feed device may be configured such that it is not a device which is suitable and / or intended for dispensing bag contents from the bag into an exterior.

The feeder may be designed differently than a Fenwell ™ device or similar device.

The "at least one UV-activatable drug" as used herein refers to a drug or drug Medicament or a combination of active substances or medicaments, which can be converted by irradiation with UV light into another, preferably active, form. Under UV light, light in a wavelength range of generally about 1 to about 380 nanometers, but especially UV-A light, understood.

Suitable UV-activatable agents include, for example, psoralens, porphyrins, various dyes, as well as combinations thereof. The UV-activatable agents suitable for treating the at least one blood component are generally known to a person skilled in the art and include u. a. the active ingredients specified in the publications EP 1 902 740 A1 or WO 2005/004862 A2, which active ingredients are hereby expressly referred to. Various UV-activatable agents can also be used according to the invention for treating the same blood components or for treating various blood components. The amount of addition of the at least one UV-activatable agent may depend on various parameters and the condition of the at least one blood component to be treated. A determination of the added amount which differs from case to case may therefore be expedient and may be based on measurements, such as concentration measurements, optical measurements and other measurements, and / or empirical values.

In a preferred embodiment, the feed device is an injection port. Such an "injection port" may be provided at any suitable position on the bag connected to the interior thereof The injection port is made of a material suitable for adding the UV-activatable active ingredient. In addition, for reasons of a sterile performance of the treatment of the at least one blood component, certain materials, such as, for example, stainless steel, medical (medical grade) plastics, are preferred, since they are particularly easy to sterilize and free of pathogens. The injection port may, for example, comprise a membrane puncturable with a syringe cannula.

In another embodiment, the pouch is suitable for introducing UV light into the interior of at least one wavelength between 315 and 380 nanometers. More preferably, the bag is suitable for introducing UV-A light into the interior with at least one wavelength between 325 and 365 nanometers. Also preferably, the bag is suitable for admitting UV light into the interior with at least one internally measurable wavelength between 334 and 346 or between 325 and 335 nanometers. Also suitable is a wavelength of UV-A light of less than 350 nanometers.

In a preferred embodiment, the pouch of the invention may be suitable for the treatment of leukocytes. The treatment of leukocytes in the pouch of the invention may serve, as described above, to assist the immune system of the body impaired in certain pathological conditions.

In a further preferred embodiment, the bag for treatment - as described above - was used by lymphocytes. For example, malignant T lymphocytes treated in the pouch of the invention may be inactivated. You can then look for repatriation trigger tumor-specific immune reactions in the patient's body and strengthen the body's own immune system.

In a further preferred embodiment of the present invention, the bag is suitable and intended to be centrifuged in order to separate at least one first blood component present in its interior from at least one second blood component also present in its interior and different from the first ,

The "suitable and / or provided for centrifuging bag" is designed so that it can withstand the forces and stresses applied during centrifugation in it, for example, a whole blood sample by centrifugation into individual blood components (plasma, leukocytes / platelets, erythrocytes ) or separation of already separated blood components by centrifugation, that is, a "sharper" interface between the individual blood components can be created.

In a further preferred embodiment, the bag according to the invention has at least two removal devices, which are provided and intended as outlets for removing blood components which are different from each other from the inside of the bag after centrifuging the bag. The removal of the individual components should preferably be able to be carried out separately from each other.

Such "removal devices" can, for example

Hoses, valves, pumping and / or suction devices and other, be suitable for this purpose facilities or provided for the connection and configured. such Devices may be made of materials that enable germ-free delivery of the various blood components for their further therapeutic and / or diagnostic use.

Furthermore, the bag may be provided with at least two supply or withdrawal means for blood components which are not the components to be treated, of which a first device is disposed in a first end portion of the bag or its interior and a second one at another end portion the bag or its interior is arranged to be configured. The supply and removal devices may be configured as suitable hose, valve, pump, suction and other suitable for this purpose devices, as exemplified above, or to connections for this purpose.

The "first means in a first end portion of the bag or its interior" may be located at a first end of the bag For example, the first means may be disposed "vertically" up the pouch and remove the lighter component, eg, the plasma component to serve the blood. The term "above" may refer to the plasma component present above the leukocyte / platelet and erythrocyte component when the bag is aligned vertically after centrifugation. which is closer to the center of rotation or has been found during centrifugation as, for example, a second end. The "second means in a second end portion of the bag or its interior" may be located at a second end of the bag. For example, this second means may be located "down" when the bag is oriented vertically and may be used to remove the red blood cell component of the blood. The term "below" may refer to the erythrocyte component present under vertical orientation of the bag after centrifugation below the plasma component and the leukocyte / platelet component "bottom" or the second

End, can be understood as the side of the bag, which is closer to the center of rotation during centrifugation or has found such. the first end.

Furthermore, the at least two feed or

Removal devices for blood components also be arranged on any other end portions of the bag or its interior. It is not necessary that the feeder removal means are provided at two opposite end portions. However, it is preferable that the supply or discharge means are not provided at the same end portion of the bag or its interior, so that from the edge of the interior of the bag - without pipe sections or the like projecting inside - two components separated from each other by centrifugation are independent of each other the inside of the bag are removable.

The object according to the invention is also solved by a bag set according to claim 11, a method according to claim 13 and a treatment device according to claim 22. To avoid a repetition of the individual components, elements and / or benefits will be related to the components of the bag according to the invention, elements and / or advantages referenced.

The bag set according to the invention comprises at least one bag according to the present invention.

In a further preferred embodiment, the bag set according to the invention may comprise at least one bag according to the present invention and at least one further bag, which is not in accordance with the invention.

In a further preferred embodiment, the bag set may comprise at least one further bag, e.g. one or more separation or component bags. The at least two bags are related

Fluid communication, especially in interruptible fluid communication. The "at least one other pouch" may be a second pouch of the invention or another suitable pouch for treating, processing, sterilizing, transporting, storing, freezing, etc. Suitable materials for such pouches include the aforementioned materials as well as all others described in U.S. Pat State of the art for the respective purpose known materials and their combinations.

An "interruptible fluid connection" between at least two bags means a connection, preferably at will and as required, between the bag to be opened or closed, which is connected by means of hoses,

Valves and other suitable for this purpose components can be executed. Furthermore, the object according to the invention is achieved by a method for treating at least one blood component using the bag according to the invention and / or a bag set according to the invention having the features of claim 13.

Such a method in a preferred embodiment comprises the step of using at least one bag according to the invention.

Such a method further comprises, in a further preferred embodiment, centrifuging a whole blood sample inside the bag, discharging at least first and second blood components from the interior of the bag leaving a buffy coat inside

Supplying at least one activatable by UV light active substance to the remaining inside the bag Buffy Coat and irradiating the bag with UV light.

The first and / or second blood components discharged from the interior of the bag may be, for example, plasma and erythrocytes. The third blood component remaining in the pouch is then buffy coat containing the leukocyte and / or platelet. In this way it is possible in an advantageous manner, according to the invention, both to separate and to treat the lymphocytes provided, for example, for the treatment of cutaneous T-cell lymphoma separately from other components in only one blood bag and without transferring to another blood bag or the like ,

The feeding of the at least one activatable by UV light active substance to the inside of the bag For example, remaining buffy coat can be made from outside the bag via the feed device described above, for example via an injection port. However, the at least one UV-activatable active substance can also be supplied within the bag from the reservoir provided therefor, initially sealed against the interior of the bag.

Subsequently, the bag can be irradiated with suitable UV light, such as UV-A light. Preferred wavelength ranges include wavelength ranges from 315 to 380 nanometers, preferably 325 to 365 nanometers, more preferably 334 to 346 nanometers and most preferably 325 to 335 nanometers, and generally UV wavelengths below 350 nanometers.

In an embodiment according to the invention, buffy coat can be understood to mean something other than a platelet concentrate or an amount of concentrated or substantially concentrated (ie completely or substantially purified of particulate or particulate blood constituents) platelets.

A refilling of the blood component to be irradiated can be omitted in an embodiment of the method according to the invention.

A transfer can be dispensed with in an embodiment of the method according to the invention.

A preferred embodiment of the invention

Method includes the step of sealing the bag or the interior of the bag. The "sealing" of the bag or of the interior of the bag may according to the invention sealing against the atmosphere and / or against components in the interior of the bag and / or against substances, which opens into the bag and / or leading out of this addition devices and / or removal devices This means, for example, according to the invention the hermetic sealing of the bag with respect to the atmosphere, so that it may be advantageous to sterilize a sterilized bag and its interior germ-free against the environment, means for suitably sealing the bag and / or the interior of the bag are well-known and can be suitably selected by a person skilled in the art according to the situation at hand Thermo-welding is one possible method among others.

The method of the invention may further comprise the step of measuring a hemoglobin and / or red blood cell concentration inside the bag.

The "hematocrit value" refers to the proportion of all cellular constituents in the volume of the blood.As it is almost exclusively dependent on the erythrocyte concentration, the hematocrit value can be used as a percentage of the hemoglobin and / or erythrocyte concentration As discussed above, it may be advantageous to increase the hematocrit of the blood component remaining inside the bag, such as the blood component

Buffy Coat, to know. Too high an erythrocyte concentration may adversely affect the treatment of the buffy coat during its irradiation. Your knowledge can be beneficial too their corresponding reduction be used or be reason for appropriately adapted irradiation.

In addition, it is also possible to measure a hemoglobin concentration. The measurement of the hemoglobin concentration may be in addition to or instead of a measurement of the erythrocyte concentration. Since hemoglobin refers to blood dye in the erythrocytes, measuring a hemoglobin concentration may also be indicative of the red blood cell concentration present inside the bag. As well as the measurement of the erythrocyte concentration, the measurement of the hemoglobin concentration can advantageously avoid contact with the interior of the bag, e.g. visually, done.

A preferred development of the method according to the invention may further comprise adding at least one substance which reduces the hemoglobin and / or erythrocyte concentration into the interior of the bag. The addition of the substance lowering the hemoglobin and / or erythrocyte concentration or the amount thereof can be determined, for example, on the basis of measuring the hemoglobin and / or

Erythrocyte concentration values are measured inside the bag. Furthermore, the addition of the substance can also be based on empirical values and / or can be determined on the basis of further measurement results which have been achieved, for example, by means of optical methods and which, if appropriate, do not allow conclusions as to the hemoglobin and / or erythrocyte concentration. The present invention is not limited to any particular measuring method in this regard. A person skilled in the art may be suitable for lowering hemoglobin and / or Determine red blood cell concentration required inside the bag.

Suitable substances for lowering the hemoglobin and / or erythrocyte concentration include physiological

Saline solutions, HAES or the like and combinations thereof.

In a further preferred embodiment of the method according to the invention, the UV-activatable

Active ingredient a psoralen. A "psoralen" is the body of a group of natural products that are found in the essential oils of various plants and have the basic structure of a coumarin with an added furan ring.Since psoralen has photosensitizing properties and, for example, sensitizes the skin to UVA radiation, it can used together with UV-A light for photoactivated chemotherapy (for example, photopheresis).

As an example of a psoralens, 5 '- (4-amino-2-oxa) butyl-4, 5', 8-trimethylpsoralen can be used as UV-activatable active ingredient. However, it is also possible to use 8-methoxypsoralen, 4'- (4-amino-2-oxa) butyl-4, 5 ', 8-trimethylpsoralen or 5' - (4-amino-2-oxa) butyl-4, 4 ', 8-trimethylpsoralen or combinations thereof are used as a UV-activatable drug. The 8-MOP or psoralen in general or any other suitable active ingredient added to the bag of the blood component to be treated rapidly enters the nucleus and forms covalent crosslinking of the DNA upon exposure to UV light. These lead to apoptosis of the cells. T lymphocytes inactivated in this way can, after being reinfused into the body, advantageously trigger a tumor-specific immune response in the body. In addition, the object according to the invention is also achieved by a treatment device with at least one device according to claim 22, in particular for the semiautomatically or fully automated carrying out of the method according to the invention.

Suitable devices can be, for example, a microprocessor with a predetermined program sequence for carrying out a method according to the invention, further components which are advantageous for executing an automated method, such as memory devices, control devices, metering devices, pumping and / or suction devices, centrifugal devices, measuring devices, such as sensors, computing devices, Have facilities for measuring, for comparing, for sealing, for sterilizing and other suitable for carrying out individual process steps facilities.

The measurement of hemoglobin and / or erythrocyte concentration, for example, can be done automatically by means of a suitable measuring device. The addition of a hemoglobin and / or erythrocyte concentration-lowering substance can - for example based on a measurement result - after comparing the measured value with a predetermined setpoint in a suitable device automatically with a for adding a hemoglobin and / or erythrocyte concentration-lowering substance take appropriate metering. However, the present invention is not limited to particular treatment devices suitable for the method of the present invention, but may also include other devices. These may be further, subsequent to the inventive method and / or prior to carrying out the inventive Control and / or regulate processes taking place. This includes, for example, but not limited to, the automated reinfusion of the treated blood components into the patient's vasculature and / or the delivery of the blood derived from that patient or other donor into the pouch of the invention.

The addition device for adding the UV-activatable active substance into the interior of the bag, which is encompassed by the bag according to the invention, can advantageously dispense with components required in the prior art while reducing the risk of possible contamination, since it is possible to dispose the at least one first blood component in the interior of the bag from the at least one second blood component in the interior of the bag, in which also the photo-treatment takes place, to separate. This advantageously eliminates the need to transfer the buffy coat from a first bag, in which the separation takes place, into a second bag, in which the photo-treatment takes place. In this case, advantageously material can be saved by a second bag such as a separate MOP bag is dispensable. This contributes advantageously to the reduction of the treatment costs. At the same time, the expenditure on equipment of a treatment device can be reduced or the manual activity can be reduced, since the requirements for the treatment of the at least one blood component can be met by a single bag according to the invention. Centrifugation is also facilitated when dispensing with an additional bag such as a separate MOP bag, as is possible with the present invention. The blood component remaining inside the bag may remain in the bag for further use or use Storage for later use without further purification or refilling for storage.

In the present invention, the blood components are taken up in the bag according to the invention, separated there and also treated. In contrast to conventional methods, the duration of treatment with the method according to the invention can be significantly reduced, u. a. since the separation can take place off-line, the dispenser is therefore not bound to the processing machine during the separation. In addition, the amount of blood component needed for the treatment or purification can be reduced, especially in the off-line method using the bag according to the invention. In turn, reducing costs and the cost of having the necessary stay in the medical or clinical facility can be reduced due to reduced time and equipment savings associated with a reduced amount of blood. Furthermore, the method according to the invention can be carried out without the use of an anticoagulant with the associated advantages known to the person skilled in the art.

A treatment device according to the invention for semi- or fully automated performance of the method according to the invention can contribute to further simplification and cost savings.

It should be noted that the invention is not limited to the treatment of blood components: any type of cell separation using a prey as described above in the following photo treatment is encompassed by the invention. The bag, the bag set and the method are designed accordingly. Furthermore, more Body fluids such as lymph, bile, urine are treated in the bag of the invention. The treatment is not limited to the sole addition of a UV-activatable drug. Furthermore, further active ingredients and / or measures for treating the component present in the interior of the bag can be used. In addition, the component to be reinfused into the patient can be supplemented after treatment with further components, such as dialysis and / or substitution fluids.

The present invention will be described by way of example with reference to the accompanying drawings. The following applies:

Fig. 1 shows a schematic side view of a bag according to the invention.

Fig. 1 shows a bag 1 with an interior 3 for receiving at least one blood component 5 for its treatment according to the present invention. The bag 1 receives the at least one blood component 5 in its interior 3.

An adding device 7 is provided on the lower left side of the bag 1 in FIG. Furthermore, at the upper end 9 of the bag 1, a first device 11 and at the lower end 13 of the bag 1, a second device 15 for supplying and / or removing blood components separated by centrifugation are provided. Another derivative 17 for blood components is also provided at the upper end 9 of the bag 1.

The bag according to the invention may in each embodiment have holders for its attachment in a centrifuging device.

Claims

claims

1. bag (1) for receiving at least one blood component (5) for treating them in one

Interior (3) of the bag (1) using UV light,

marked by

an adding device (7) for adding at least one UV-activatable active substance into the interior (3) of the bag (1).

2. bag (1) according to claim 1, wherein the feed device is a Zuspritzport (7).

3. A bag (1) according to any one of claims 1 or 2, which is suitable for introducing UV light into the interior (3) with at least one wavelength between 315 and 380 nanometers.

4. bag (1) according to claim 3, which is suitable for introducing UV light into the interior (3) with at least one wavelength between 325 and 365 nanometers.

5. bag (1) according to claim 4, which is suitable for introducing UV light into the interior (3) with at least one wavelength between 334 and 346, in particular between 325 and 335, nanometers.

6. bag (1) according to any one of the preceding claims for the treatment of leukocytes.

7. bag (1) according to any one of the preceding claims for the treatment of lymphocytes.

8. bag (1) according to any one of the preceding claims, which is suitable and / or provided to the

Separation of at least one first blood component (5) present in its interior (3) from at least one second internal blood component, different from the first blood component, to be centrifuged.

9. bag (1) according to one of the preceding claims with at least two removal devices (11, 15, 17), which as outlets for removing each different blood components from the interior (3) of the bag (1) after centrifuging the bag ( 1) are provided and / or determined.

10. Bag (1) according to one of the preceding claims with at least two supply or withdrawal devices (11, 15, 17) for blood components, which are not to be treated components, of which a first device (11) in one first end portion (9) of the bag (1) or its interior (3) and a second means (15) at another end portion (13) of the bag (1) or its interior (3) is arranged.

11. Bag set with at least one bag (1) according to one of claims 1 to 10.

12. Bag set according to claim 11 with at least one further bag, wherein the at least two bags standing in interruptible fluid communication with each other.

13. A method for treating at least one blood component using the bag (1) according to one of claims 1 to 10 and / or a bag set according to one of claims 11 or 12.

14. The method according to claim 13 with the further steps:

Centrifuging a whole blood sample inside (3) the bag (1);

Discharging at least a first and / or a second blood component from the interior of the bag (1) leaving a buffy coat (5);

Supplying at least one UV-activatable active substance to the buffy coat (5) remaining in the interior (3) of the bag (1); and

Irradiate the bag (1) with UV light.

15. The method of claim 14 with the further step:

Sealing the bag (1) or the interior (3) of the bag (1).

16. The method according to any one of claims 13 to 15, further comprising the step:

Measuring a hemoglobin and / or erythrocyte concentration inside (3) of the bag (1).

17. The method according to any one of claims 13 to 16, further comprising the step:

Adding at least one hemoglobin and / or erythrocyte concentration-lowering substance into the interior (3) of the bag (1).

18. The method according to any one of the preceding claims, wherein the UV active ingredient is a psoralen.

A process according to claim 18 wherein the psoralen is 5 '- (4-amino-2-oxa) butyl-4,5', 8-trimethylpsoralen or 8-methoxypsoralen or 5 '- (4-amino-2-oxa) butyl 4, 4 ', 8-trimethylpsoralen or ^4λ - (4-amino-2-oxa) butyl-4, ^5x , 8-trimethylpsoralen or combinations thereof.

20. The method according to any one of the preceding claims, wherein the bag (1) is irradiated with UV-A light.

21. The method of claim 20, wherein the bag (1) with UV-A light having a wavelength of 315 to 380 nanometers, preferably from 325 to 365 nanometers, more preferably from 334 to 346 nanometers, and most preferably from 325 to 335 Nanometer is irradiated.

22. A treatment device with at least one device for carrying out the method according to one of claims 13 to 21.